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Abstract:  Akt  plays  an  important  role  in  the  inhibition  of  apoptosis  induced  by 
chemotherapy  and  other  stimuli.  We  therefore  investigated  if  knockdown  of  Akt2 
promoted drug-induced apoptosis in cultured osteosarcoma cells in vitro. SAOS-2 cells 
were  transfected  with  Akt2  siRNA.  The  sensitivity  of  the  transformed  cell  line  to  the 
chemotherapeutic drug cisplatin was assessed. Reduced expression of Akt2 did not directly 
inhibit the growth rate of the transfected cells; however, it significantly increased their 
sensitivity to cisplatin. Knockdown of Akt2, together with cisplatin treatment, promoted 
the expression of p53 up-regulated modulator of apoptosis (PUMA). It is possible that the 
augmentation of cisplatin cytotoxicity may be mediated by PUMA activation. The results 
of this study suggest that knockdown of Akt2 expression may have therapeutic applications 
in enhancing the efficacy of chemotherapy in patients with osteosarcoma. 
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1. Introduction 
Primary osteosarcoma is the most common bone tumor, and occurs predominantly in adolescents 
and young adults [1]. Even after the introduction of aggressive chemotherapy and wide excision of 
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tumors,  30–50%  of  patients  with  initially  localized  disease  subsequently  develop  recurrence,  with 
subsequently  poor  clinical  outcomes.  Moreover,  20–30%  of  newly  diagnosed  cases  present  with 
metastatic  disease  [2,3].  The  identification  of  the  effector  molecules  and/or  signal  transduction 
pathways responsible for regulating carcinogenesis and malignant development is therefore crucial for 
understanding  and  isolating  potential  molecular  targets  that  could  be  used  to  disrupt  the  tumor 
machinery, whilst protecting the integrity and function of normal tissue. 
Akt is a serine/threonine kinase that plays a central role in tumorigenesis. Among the members of 
Akt  family,  Akt2  is  associated  with  the  development  of  human  cancers.  Recent  reports  have 
demonstrated that the PI3K/Akt pathway is a potent survival signal that may mediate resistance to the 
apoptotic effects of chemotherapy and radiation therapy in a variety of cancer types [4–6].  
p53 up-regulated modulator of apoptosis (PUMA) is an essential mediator of cell death and plays a 
key functional role in the process of p53-mediated apoptosis [7,8]. PUMA activation was recently 
reported  to  be  a  mechanism  for  the  augmentation  of  cisplatin  cytotoxicity  in  QBC939  cells  [9].  
Alison et al. [10] recently found that Akt2 inhibition enhanced the inhibitory effects of PUMA on 
melanoma cell survival in vitro and on melanoma tumor growth in vivo.  
In this study, we investigated the hypothesis that knockdown of Akt2 plays an important role in 
osteosarcoma cell chemosensitivity to cisplatin-induced apoptosis through upregulation of PUMA. 
2. Materials and Methods  
2.1. Cell Culture  
The  human  osteosarcoma  cell  line  SAOS-2  was  obtained  from  the  American  Type  Culture 
Collection  (Manassas,  VA,  USA)  and  was  maintained  in  Dulbecco’s  Modified  Eagle’s  Medium 
(DMEM)  supplemented  with  10%  fetal  bovine  serum,  penicillin  (100  U/mL)  and  streptomycin  
(100 U/mL) at 37 ° C in an atmosphere of 5% CO2. 
2.2. Immunohistochemistry  
SAOS-2 cells were plated at a density of 5 ×  10
4/mm
2 in culture dishes for 24 h. After incubation, 
dishes  were  washed  twice  with  cold  saline.  Subsequently,  the  cells  in  the  dishes  were  fixed  in  
0.3 mol/L NaCl in 70% ethanol for 30 min. The fixed cells were lysed in 0.12 N HCl in 70% ethanol 
for 10 min and washed with PBS for 5 min three times. The cells were incubated with 1% normal 
horse serum in PBS for 30 min at room temperature. After washes with PBS for 5 min, Anti-Akt1  
(B-1)(1:100, Santa Cruz), Anti-Akt2 (1:100, Cell Signaling Technology, Inc., Beverly, MA, USA) and 
Anti-Akt3 (M-14) (1:100, Cell Signaling Technology) was used as the primary antibody, followed by 
the  rabbit  ABC  staining  system.  Protein-positive  cells  were  counted  by  light  microscopy  at  × 200 
magnification and expressed as the number of positive cells per 1000 cancer cells.  
2.3. Small Interference (siRNA) Transfection 
The  following  siRNA  sequences  were  utilized  in  this  study:  Akt2-siRNA  (sense  
5'-UGCCCUUCUACAACCAGGAdTdT-3'), Akt-3m-siRNA (control siRNA for transfection) (sense 
5'-UGCCGUUCUUCAACGAGGAdTdT-3')  [11].  The  siRNA  oligonucleotides,  together  with  the Int. J. Mol. Sci. 2011, 12                    
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corresponding antisense oligonucleotides, were synthesized by Dharmacon (Lafayette, CO, USA). The 
control  siRNA  was  from  Ambion  (Austin,  TX,  USA).  siRNA  transfection  was  performed  using 
Lipofectamine 2000, according to the manufacturer's instructions, and following procedures described 
previously  [12].  Pilot  experiments  were  performed  to  optimize  the  amount  and  time  of  maximal 
protein knockdown. Cells were treated with cisplatin following siRNA transfection, during the period 
of maximal protein knockdown.  
2.4. Cell Proliferation and Cytotoxicity Assay 
The effects of Akt2 silencing on growth of SAOS-2 cells were assessed by culturing control cells 
and cells transfected with Akt2-siRNA in the presence of 1 μg/mL cisplatin for 48 h. Cells from these 
precultures were seeded at 3 ×  10
3 cells/well into 96-well plates and allowed to attach for 12 h. Growth 
was then measured by determining the numbers of living cells using the MTT method. The results are 
expressed as percentage of viable cells at the start of the experiment. 
For cytotoxicity assays, 5 ×  10
3 cells/well were plated in 96-well plates and incubated overnight. 
The medium was then replaced with fresh medium containing different concentrations of cisplatin  
(Eli Lilly, Geneva, Switzerland) and incubation was continued for 48 h. Cisplatin (1 μg/mL) was 
present throughout the experiment. Cell viability was determined using the MTT method. Percent 
survival was defined as 100 ×  (T − T0)/(C − T0) when (T − T0) = 0. When the T value was less than T0, 
cell killing had occurred and the cytotoxic  activity was determined as  (T − T0)/T0 expressed as a 
percentage. T is the optical density (OD)540 value at the time-point in question, and T0 is the OD540 
value at the moment of drug addition. C indicates the OD540 value of the untreated control group at the 
time-point in question. IC50 values were calculated from three independent experiments. 
2.5. Apoptosis Detection by Enzyme-Linked Immunosorbent Assay (ELISA) 
This assay was performed using the cell death detection ELISAPLUS kit (Roche Applied Sciences, 
Indianapolis, IN, USA), according to the manufacturer’s instructions. Cells of both transfected and 
untransfected cells were plated on 6-well plates and treated with different indicated concentrations of 
cisplatin, after which both adherent and floating (apoptotic) populations were harvested. Cells were 
lysed in NP-40 lysis buffer and nucleosomes in the supernatant were detected photometrically using an 
ELISA plate Reader (SpectraMax 190, Molecular Devices Ca). The readings were expressed as degree 
of apoptosis relative to the untreated control, which was scored as 1.  
2.6. Analysis of Apoptosis by DAPI Staining 
For  apoptosis  analysis,  both  adherent  and  non-adherent  cells  were  harvested  after  cisplatin 
treatment and their cell morphologies were examined by microscopy. DNA damage characteristic of 
apoptosis was identified by staining with 4’,6-diamidino-2-phenylindole (DAPI). Briefly, cells were 
harvested, washed, and fixed in 3.7% formaldehyde at room temperature for 15 min. After treatment 
with RNase A, samples were stained with 1 μg/mL of DAPI (Sigma USA) in phosphate-buffered 
saline (PBS) for 15 min at room temperature, rinsed in PBS, and analyzed using a Leica DM RXE 
fluorescence microscope (Leica, Wetzlar, Germany). Apoptotic cells were defined by the condensation 
of nuclear chromatin, fragmentation, or margination to the nuclear membrane. Int. J. Mol. Sci. 2011, 12                    
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2.7. Western Blotting 
Cells were lysed in 250 mM NaCl, 50 mM Hepes (pH 7), 0.1% Nonidet P-40, and 1 μM proteinase 
inhibitor cocktail (Roche, Basel, Switzerland). Protein concentration was determined using the BCA 
protein assay (Pierce Chemical  Company, Rockford,  IL, USA). Equal amounts  of cellular protein  
(20  μg/sample)  were  electrophoresed  on  12%  sodium  dodecyl  sulfate-polyacrylamide  gels  and 
transferred  to  nitrocellulose  membranes  (Amersham  Pharmacia  Biotech,  Zurich,  Switzerland). 
Depending on the experiment, the membranes were first incubated with polyclonal rabbit antibody to 
phospho-AKT (serine-473) (Biosource International Inc., Camarillo, CA, USA), polyclonal antibody 
to  AKT2  (Cell  Signaling  Technology,  Inc.,  Beverly,  MA,  USA),  polyclonal  antibody  to  PUMA  
(Santa  Cruz  Biotechnology,  Santa  Cruz,  CA,  USA),  or  polyclonal  antibody  to  actin  (Santa  Cruz 
Biotechnology, Inc.). For signal detection, the blots were then incubated with peroxidase-coupled goat 
anti-rabbit  immunoglobulin  (Amersham  Pharmacia  Biotech).  Enhanced  chemiluminescence  
(ECL,  Amersham  Pharmacia  Biotech)  reagents  were  used  to  detect  the  signals,  according  to  the 
manufacturer’s instructions. 
2.8. Wt-P53 Assay 
A commercial ELISA kit (Calbiochem) was used to analyze the cellular level of wt-P53. Briefly, an 
anti-wt-P53 monoclonal antibody (Merck-Calbiochem) was precoated onto the 96-well microtiter plate. 
Cells  (5 ×  10
5) of transfected and untransfected  treated with  different  indicated  concentrations  of 
Cisplatin for 48 h was then added to the well. The plate was incubated at room temperature for 2 h and 
the wash was repeated. A substrate solution was then added to all wells and incubated for 30 min. At 
this point, a stop solution was added to all wells. Color development and intensity of the color were 
measured using an ELISA plate reader according to the manufacturer’s instructions. A standard curve 
was prepared, plotting the absorbance versus the concentration of the wt-P53 expressed as picogram 
per milliliter in the original samples. 
2.9. Statistical Analysis 
Data are presented as mean ±  SD. P values were calculated using Student’s t tests or two-way analysis 
of variance (ANOVA) using SPSS10.0 software. P < 0.05 was considered to be statistically significant.  
3. Results 
3.1. Akt 1,2,3 Expression in SAOS-2 Cells 
Figure 1 shows the representative expression patterns of Akt1, Akt2 and Akt3 in SAOS-2 cells. 
Significant Akt2 staining was seen in the cytoplasm. No obvious Akt1 and Akt3 staining was shown in 
the SAOS-2 cells.In the present study, Akt2 was used for further study. Int. J. Mol. Sci. 2011, 12                    
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Figure 1. Immunohistrology analysis of levels of Slug protein in Akt 1, Akt2 and Akt3 in 
SAOS-2 cells. Significant Akt2 staining was seen in the cytoplasm. No obvious Akt1 and 
Akt3 staining was shown (BAC ×  200). 
 
3.2. Akt2 siRNA Transfection Did not Inhibit SAOS-2 Cell Growth 
SAOS-2 cells were transfected with Akt2-siRNA orAkt-3m-siRNA for 72 h. Figure 2A shows the 
results of Western blotting and the relative expression levels of Akt2/pAkt at different times after 
transfection.  Akt2  protein  expression  was  decreased  in  Akt2-siRNA-transfected  cells.  MTT  and 
ELISA  were  performed  to  determine  the  effects  of  Akt2  siRNA  transfection  on  growth  rate  and 
apoptosis.  Untransfected  control  cells,  cells  transfected  with  control  Akt-3m-siRNA,  and  cells 
transfected with Akt2-siRNA exhibited similar growth and apoptosis rates (Figure 2B,C). Knockdown 
of Akt2 thus had no apparent direct effect on host cell growth and apoptosis, as documented for other 
cancer cell lines [13]. 
3.3. Knockdown of Akt2 Sensitizes SAOS-2 Cells to Chemotherapeutic Agents 
Knockdown of Akt2 in SAOS-2 cells increased their susceptibility to cisplatin. Figure 3 shows the 
decrease in cell viability as a function of drug concentration following treatment with cisplatin for 48 h. 
Akt2-siRNA-transfected  SAOS-2  cells  were  significantly  more  sensitive  to  cisplatin  compared  
with  both  untransfected  and  Akt-3m-siRNA-transfected  parent  cells.  The  reduced  survival  of  
Akt2-siRNA-transfected SAOS-2 cells was most pronounced at low drug concentrations. There was no 
significant difference in survival between Akt-3m-siRNA-transfected cells and parent SAOS-2 cells 
(Figure 3A). The mean IC50 for cisplatin in Akt2-siRNA-transfected cells was 4.8 μM, compared to 
41.4 μM for control cells (Figure 3B). This corresponds to a 9-fold increase in chemosensitivity.  
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Figure 2. The effect of Akt2 siRNA transfection on SAOS-2 cell growth. (A) SAOS-2 
cells were transfected with Akt2-siRNA or control Akt-3m-siRNA for 12–72 h, after which 
Akt2 and pAkt expression levels were analyzed by Western blotting. The expression levels 
of  Akt2  and  pAkt  relative  to  actin  are  indicated.  Akt2/pAkt  expression  was  lowest  in  
Akt2-siRNA-transfected cells after transfection for 48 h; (B) ELISA was used to measure 
the apoptosis rates in Akt2-siRNA and Akt-3m-siRNA-transfected cells after transfection 
for 48 h. The apoptosis rates were similar in Akt2-siRNA-transfected, Akt-3m-siRNA-
transfected and control cells (* P > 0.05 vs. control); (C) The MTT method was used to 
measure the cell growth rates in Akt2-siRNA- and Akt-3m-siRNA-transfected cells after 
transfection for 48 h. The growth rates were similar in Akt2-siRNA- and Akt-3m-siRNA-
transfected and control cells (* P > 0.05 vs. control). 
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Figure  3.  Knockdown  of  Akt2  sensitizes  SAOS-2  cells  to  chemotherapeutic  agents.  
(A) Cytotoxicity of cisplatin in SAOS-2 cells, SAOS-2 cells transfected with Akt2-siRNA 
and SAOS-2 cells transfected with Akt-3m-siRNA. Cells were treated with cisplatin at the 
indicated concentrations for 48 h. Percent survival was determined using the MTT assay. 
Each point represents  the mean ±  SD (error bars) from  three independent  experiments  
(** P < 0.05, * P < 0.05 vs. control); (B) IC50 values for cisplatin in the different cell lines. 
The IC50 values were determined after 48 h of exposure to cisplatin and were defined as the 
concentration causing 50% growth inhibition in treated cells, compared to that in control 






Treatment of Akt2-siRNA-transfected SAOS-2 cells with low concentrations of cisplatin (1 μM) 
resulted  in  morphological  changes  typical  of  apoptosis,  such  as  cell  shrinkage,  rounding  and 
detachment of the cells from the plate, as observed by phase contrast microscopy (not shown). DAPI 
staining was used to visualize nucleosomal DNA damage. Nuclear fragmentation and apoptotic bodies 
were clearly apparent in Akt2-siRNA-transfected SAOS-2 treated with cisplatin (1 μM), while no 
nuclear fragmentation or apoptotic bodies were seen in Akt-3m-siRNA-transfected or untransfected 
SAOS-2 cells treated with cisplatin (1 μM) (Figure 4A). ELISA analysis determined that the apoptosis 
rate  in  Akt2-siRNA-transfected  SAOS-2  cells  treated  with  cisplatin  (1  μM)  was  higher  than  in 
similarly-treated Akt-3m-siRNA-transfected or untransfected SAOS-2 cells (P < 0.05) (Figure 4B). Int. J. Mol. Sci. 2011, 12                    
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Figure 4. DAPI staining and ELISA for detection of apoptotic cells. (A) Untransfected, 
Akt2-siRNA-transfected, and Akt-3m-siRNA-transfected SAOS-2 cells were treated with 
cisplatin (1 μM) for 48 h and then fixed and stained with DAPI. Morphological changes 
were visualized by fluorescence microscopy. Nuclear fragmentation and apoptotic bodies 
were clearly  apparent  in Akt2-siRNA-transfected cells,  while no nuclear fragmentation  
or  apoptotic  bodies  were  seen  in  Akt-3m-siRNA-transfected  or  untransfected  SAOS-2  
cells  treated  with  cisplatin  (1  μM);  (B)  Untransfected,  Akt2-siRNA-transfected,  and  
Akt-3m-siRNA-transfected SAOS-2 cells treated with cisplatin (1 μM) for 48 h. At the end 
of incubation cells were harvested and apoptosis assays were performed using a cell death 
detection  ELISAPLUS  kit.  Data  in  each  set  represents  the  mean  ±   S.D.  of  three 




3.5. Effects of cisplAtin Exposure on Activation of Akt2 
Following exposure to apoptotic stimuli, SAOS-2 cells may engage survival mechanisms to subvert 
the induction of cell death. Activation of the Akt2 signaling pathway has been observed following 
exposure  of  diverse  cancer  cell  types  to  various  chemotherapeutic  agents.  In  the  present  study,  
SAOS-2 cells were treated with cisplatin (10 μM) and the pAkt levels were examined over a period of 
2–6 h. Cisplatin treatment induced a rapid increase in Akt2/pAkt levels (Figure 4).  Int. J. Mol. Sci. 2011, 12                    
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Figure 5. Determination of total Akt2 and phospho-Akt (pSer473) by Western blotting 
following  treatment  of  SAOS-2  cells  with  cisplatin.  SAOS-2  cells  were  treated  with 
cisplatin  (10  μM)  and  the  Akt2/pAkt  levels  were  examined  over  a  period  of  2–6  h. 
Cisplatin treatment induced a rapid increase in Akt2/pAkt levels. 
 
3.6. Knockdown of Akt2 Combined with Cisplatin Treatment Upregulates PUMA 
Chemotherapeutic agents have previously been found to activate PUMA [9]. In the present study, 
treatment  of  Akt2-siRNA-transfected  SAOS-2  with  cisplatin  (10  μM)  for  2–6  h  induced  a  rapid 
increase  in  PUMA  levels  (Figure  6).  These  findings  suggest  that  sensitization  of  cells  by  Akt2 
silencing proceeds via PUMA activation. 
Figure  6.  Knockdown  of  Akt2  combined  with  cisplatin  treatment  upregulates  PUMA. 
Western  blot  analysis  of  PUMA  in  untransfected,  Akt2-siRNA-transfected,  and  
Akt-3m-siRNA-transfected  SAOS-2  cells  treated  with  cisplatin  (10  μM)  for  2–6  h.  
A rapid increase in PUMA levels occurred in  Akt2-siRNA-transfected SAOS-2 treated  
with cisplatin. 
 
3.7. Apoptosis Induction by Akt2 Knockdown and Cisplatin Treatment Is p53 Independent 
To  determine  whether  apoptosis  induction  by  Akt2  knockdown  and  cisplatin  treatment  is  p53 
independent,  ELISA  method  was  used  to  detect  wt-P53  level  in  SAOS-2  cells  treated  with  Akt2 
knockdown and/or cisplatin treatment (1, 5 and 10 μM). As shown in Figure 7, no detectable wt-P53 
protein was shown in untransfected, Akt2-siRNA-transfected, and Akt-3m-siRNA-transfected SAOS-2 Int. J. Mol. Sci. 2011, 12                    
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cells,  respectively. Although the wt-P53 level  increased the cisplatin  dose dependence, it was  not 
significant (P > 0.05). 
Figure 7. ELISA assay of wt-P53 in the supernatant medium. No detectable wt-P53 protein 
was  shown  in  untransfected,  Akt2-siRNA-transfected,  and  Akt-3m-siRNA-transfected 
SAOS-2  cells,  respectively.  Although  the  wt-P53  level  increased  the  cisplatin  dose 
dependence, it was not significant (P > 0.05). 
 
4. Discussion 
The  therapeutic  advantages  of  cisplatin,  such  as  high  efficiency,  mild  side  effects  and  easy 
administration, mean that it is still one of the most commonly used chemotherapeutic agents. However, 
resistance  to  cisplatin  often  occurs,  and  methods  of  enhancing  the  sensitivity  of  cancer  cells  to 
cisplatin-induced apoptosis have therefore become an important chemotherapeutic strategy. 
The PI3K/Akt survival pathway is activated by survival signals such as growth factors, cytokines, 
hormones  and  oncogenic  Ras  [14].  Activation  of  Akt  favors  survival  via  the  direct  regulation  of 
apoptotic proteins, including the Bcl-2 members Bad and Bcl-xl or caspase 9 [15–18]. Akt signaling 
has  recently  been  shown  to  mediate  therapeutic  resistance.  The  PI3K/Akt  pathway  is  frequently 
overexpressed/activated in cancers, and Akt activation promotes a chemoresistant phenotype, whereas 
Akt inhibition sensitizes chemoresistant cells to cisplatin-induced apoptosis. 
In the present study, inhibition of Akt2 had minimal effect on the basal level of apoptosis, though it 
reduced the threshold for the induction of apoptosis in response to chemotherapy in SAOS-2 cells. 
These data suggest that targeted inhibition of the Akt2 pathway may not be an adequate therapy when 
administered alone. However, we also examined the ability of Akt2 inhibition to sensitize SAOS-2 
cells, and demonstrated increased apoptosis after combined Akt2 inhibition and cisplatin treatment, 
suggesting  that  high  basal  Akt2  activity  is  required  for  the  efficacy  of  this  targeted  therapy.  The 
mechanism by which Akt2 inhibition confers chemosensitivity in these cancer cells is unclear, but it 
appears to involve the regulation of transcription factors and proapoptotic proteins, such as PUMA. 
Recent evidence suggests that upregulation of PUMA is an important mechanism in cisplatin-induced 
apoptosis  [19],  and  Akt  contributes  to  chemoresistance  by  attenuating  p53-mediated  PUMA 
upregulation and phosphorylation of p53, which are essential but independent determinants of cisplatin 
sensitivity  [20].  The  results  of  this  study  showed  that  SAOS-2  cells  responded  to  chemotherapy Int. J. Mol. Sci. 2011, 12                    
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exposure with the induction of an Akt2-dependent survival pathway that may involve Akt2-mediated 
transcriptional inhibition of the proapoptotic PUMA gene. Akt2 inhibition enhanced the proapoptotic 
effect of chemotherapy via upregulating the induction of PUMA. To determine whether apoptosis 
induction by Akt2 knockdown and cisplatin treatment is p53 independent, ELISA method was used to 
detect wt-P53 level in SAOS-2 cells treated with Akt2 knockdown and /or cisplatin treatment. The 
results showed that although the wt-P53 level increased in a cisplatin dose dependent manner, it was 
not significant. It was also proven that apoptosis induction by Akt2 knockdown and cisplatin treatment 
is p53 independent. 
Chemotherapy appears to wield a double-edged sword; although it is able to induce apoptosis in 
cancer cells, it is also able to stimulate the tumor cells’ native survival mechanisms. In the present 
study,  SAOS-2  cells  on  the  one  hand  responded  to  chemotherapy  exposure  by  induction  of  an  
Akt2-dependent  survival  pathway,  while  on  the  other  hand,  chemotherapy  exposure  induced 
proapoptotic PUMA signaling. The benefits of combining Akt2 inhibition with standard chemotherapy 
thus  appear  to  be  twofold;  disruption  of  the  Akt2  survival  pathway  in  cancer  cells  that  harbor 
constitutively active Akt may induce an apoptotic response, while inhibition of Akt may abrogate the 
undesired survival response seen when tumor cells are exposed to chemotherapy. The chemoresistance 
of SAOS-2 cells may be both a manifestation of their inherent properties, but may also reflect their 
ability to respond to an apoptotic stimulus with the induction of a robust cell survival response that 
circumvents the proapoptotic effect of chemotherapy. 
5. Conclusions 
Akt2  blocks  PUMA  upregulation  induced  by  cisplatin  in  SAOS-2  cells,  thereby  conferring 
resistance to cisplatin-induced apoptosis. Inhibition of this survival response represents an attractive 
method for chemosensitization of this lethal malignancy, and the results of the current study confirm 
the Akt/PUMA pathway as an appropriate therapeutic target. 
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